New combo therapy tested for Tough-to-Treat lung cancer
NCT ID NCT04224337
Summary
This study tested a combination of three drugs—an immunotherapy (durvalumab) plus two chemotherapies (doxorubicin and ifosfamide)—in patients with a rare and aggressive form of non-small cell lung cancer called pulmonary sarcomatoid carcinoma (PSC). The main goal was to see if this combination could effectively shrink tumors and control the disease. Researchers also closely monitored side effects and how long patients lived without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seoul National University Hospital
Seoul, Seoul, South Korea
Conditions
Explore the condition pages connected to this study.